BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 1321426)

  • 1. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.
    Gavioli R; De Campos-Lima PO; Kurilla MG; Kieff E; Klein G; Masucci MG
    Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5862-6. PubMed ID: 1321426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
    Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
    Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
    Masucci MG; Torsteindottir S; Colombani J; Brautbar C; Klein E; Klein G
    Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4567-71. PubMed ID: 3037521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.
    Murray RJ; Wang D; Young LS; Wang F; Rowe M; Kieff E; Rickinson AB
    J Virol; 1988 Oct; 62(10):3747-55. PubMed ID: 2843672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
    J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues.
    de Campos-Lima PO; Levitsky V; Brooks J; Lee SP; Hu LF; Rickinson AB; Masucci MG
    J Exp Med; 1994 Apr; 179(4):1297-305. PubMed ID: 7511684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell recognition of Epstein-Barr virus associated lymphomas.
    Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
    Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
    Khanna R; Burrows SR; Kurilla MG; Jacob CA; Misko IS; Sculley TB; Kieff E; Moss DJ
    J Exp Med; 1992 Jul; 176(1):169-76. PubMed ID: 1377222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.
    Murray RJ; Kurilla MG; Griffin HM; Brooks JM; Mackett M; Arrand JR; Rowe M; Burrows SR; Moss DJ; Kieff E
    Proc Natl Acad Sci U S A; 1990 Apr; 87(8):2906-10. PubMed ID: 2158098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.
    Gavioli R; Kurilla MG; de Campos-Lima PO; Wallace LE; Dolcetti R; Murray RJ; Rickinson AB; Masucci MG
    J Virol; 1993 Mar; 67(3):1572-8. PubMed ID: 7679748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha up-regulates the expression of HLA class I determinants in Burkitt lymphoma lines.
    Avila-Carino J; Torsteinsdottir S; Bejarano MT; Klein G; Klein E; Masucci MG
    Cell Immunol; 1988 Dec; 117(2):303-11. PubMed ID: 2848629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
    Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
    Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of integrated Epstein-Barr virus nuclear antigen 1 and 2 genes in a Burkitt lymphoma cell line after somatic cell fusion with autologous EBV-immortalized lymphoblastoid cells.
    Wolf J; Pawlita M; Klevenz B; Frech B; Freese UK; Müller-Lantzsch N; Diehl V; zur Hausen H
    Int J Cancer; 1993 Feb; 53(4):621-7. PubMed ID: 8382194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis.
    Jäger M; Benninger-Döring G; Prang N; Sylla BS; Laumbacher B; Wank R; Wolf H; Schwarzmann F
    Int J Cancer; 1998 May; 76(5):694-701. PubMed ID: 9610728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations.
    Chu PG; Chang KL; Chen WG; Chen YY; Shibata D; Hayashi K; Bacchi C; Bacchi M; Weiss LM
    Am J Pathol; 1999 Sep; 155(3):941-7. PubMed ID: 10487851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.
    Levitsky V; Zhang QJ; Levitskaya J; Masucci MG
    J Exp Med; 1996 Mar; 183(3):915-26. PubMed ID: 8642295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2.
    Khanna R; Burrows SR; Suhrbier A; Jacob CA; Griffin H; Misko IS; Sculley TB; Rowe M; Rickinson AB; Moss DJ
    J Immunol; 1993 Jun; 150(11):5154-62. PubMed ID: 7684421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1.
    Stuber G; Dillner J; Modrow S; Wolf H; Székely L; Klein G; Klein E
    Int Immunol; 1995 Apr; 7(4):653-63. PubMed ID: 7547693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines.
    Finke J; Rowe M; Kallin B; Ernberg I; Rosén A; Dillner J; Klein G
    J Virol; 1987 Dec; 61(12):3870-8. PubMed ID: 2824821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.